Patents by Inventor William Ronald Solvibile

William Ronald Solvibile has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL STING AGONISTS
    Publication number: 20220048936
    Abstract: The present invention provides compounds of Formula I?: wherein W, X, Y, Z, Z1, Z2, R1, R2, R3, R4 and R5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.
    Type: Application
    Filed: September 7, 2021
    Publication date: February 17, 2022
    Applicant: Venenum Biodesign, LLC
    Inventors: David J. DILLER, Axel METZGER, David E. KAELIN, JR., Steven PAGET, Chia-Yu HUANG, Brian F. MCGUINNESS, Audrey Julie HOSPITAL, William Ronald SOLVIBILE, JR.
  • Sting agonists
    Patent number: 11161864
    Abstract: The present invention provides compounds of Formula I?: wherein , W, X, Y, Z, Z1, Z2, R1, R2, R3, R4 and R5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: November 2, 2021
    Assignee: VENENUM BIODESIGN, LLC
    Inventors: David J. Diller, Axel Metzger, David E. Kaelin, Jr., Steven Paget, Chia-Yu Huang, Brian F. Mcguinness, Audrey Julie Hospital, William Ronald Solvibile, Jr.
  • NOVEL STING AGONISTS
    Publication number: 20200131209
    Abstract: The present invention provides compounds of Formula I?: wherein , W, X, Y, Z, Z1, Z2, R1, R2, R3, R4 and R5 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are effective at modulating the STING protein and thus can be used as medicaments for treating or preventing disorders affected by the agonism of STING.
    Type: Application
    Filed: October 24, 2019
    Publication date: April 30, 2020
    Inventors: David J. Diller, Axel Metzger, David E. Kaelin, JR., Steven Paget, Chia-Yu Huang, Brian F. Mcguinness, Audrey Julie Hospital, William Ronald Solvibile, JR.
  • N-substituted-azacyclylamines as histamine-3 antagonists
    Patent number: 7935719
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor: wherein the variables are described in the specification.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: May 3, 2011
    Assignee: Wyeth LLC
    Inventors: William Ronald Solvibile, Ji-In Kim, Marla Jean Williams, Jonathan Laird Gross, Albert Jean Robichaud
  • N-substituted-azacyclylamines as histamine-3 antagonists
    Patent number: 7820825
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.
    Type: Grant
    Filed: March 14, 2007
    Date of Patent: October 26, 2010
    Assignee: Wyeth LLC
    Inventors: Derek Cecil Cole, Magda Asselin, Joseph Raymond Stock, Albert Jean Robichaud, Ji-In Kim, William Ronald Solvibile, Jonathan Laird Gross
  • Amino-pyridines As Inhibitors Of Beta-secretase
    Publication number: 20100204245
    Abstract: The present invention provides an amino-pyridine compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.
    Type: Application
    Filed: April 20, 2010
    Publication date: August 12, 2010
    Applicant: Wyeth LLC
    Inventors: Michael Sotirios Malamas, William Floyd Fobare, William Ronald Solvibile, JR., Frank Eldridge Lovering, Jeffrey Scott Condon, Albert Jean Robichaud
  • Amino-5-(5-membered)heteroarylimidazolone Compounds And The Use Thereof For Beta-secretase Modulation
    Publication number: 20100168106
    Abstract: The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles
    Type: Application
    Filed: March 8, 2010
    Publication date: July 1, 2010
    Applicant: Wyeth LLC
    Inventors: Michael Sotirios Malamas, Ping Zhou, William Floyd Fobare, William Ronald Solvibile, Iwan Suwandi Gunawan, James Joseph Erdei, Yinfa Yan, Patrick Michael Andrae, Dominick Anthony Quagliato
  • Amino-pyridines as inhibitors of ?-secretase
    Patent number: 7732457
    Abstract: The present invention provides an amino-pyridine compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.
    Type: Grant
    Filed: January 31, 2006
    Date of Patent: June 8, 2010
    Assignee: Wyeth LLC
    Inventors: Michael Sotirios Malamas, William Floyd Fobare, William Ronald Solvibile, Jr., Frank Eldridge Lovering, Jeffrey Scott Condon, Albert Jean Robichaud
  • Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for ?-secretase modulation
    Patent number: 7705030
    Abstract: The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: April 27, 2010
    Assignee: Wyeth LLC
    Inventors: Michael Sotirios Malamas, Ping Zhou, William Floyd Fobare, William Ronald Solvibile, Iwan Suwandi Gunawan, James Joseph Erdei, Yinfa Yan, Patrick Michael Andrae, Dominick Anthony Quagliato
  • AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION
    Publication number: 20080306091
    Abstract: The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles
    Type: Application
    Filed: July 28, 2008
    Publication date: December 11, 2008
    Applicant: Wyeth
    Inventors: Michael Sotirios Malamas, Ping Zhou, William Floyd Fobare, William Ronald Solvibile, Iwan Suwandi Gunawan, James Joseph Erdei, Yinfa Yan, Patrick Michael Andrae, Dominick Anthony Quagliato
  • Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators
    Patent number: 7459567
    Abstract: The present invention provides a substituted thienyl or furyl acylguanidine compound of formula I The present invention also provides methods for the inhibition of ?-secretase (BACE) and for the treatment of ?-amyloid deposits and neurofibrillary tangles.
    Type: Grant
    Filed: February 13, 2006
    Date of Patent: December 2, 2008
    Assignee: Wyeth
    Inventors: William Floyd Fobare, William Ronald Solvibile, Jr.
  • Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for ?-secretase modulation
    Patent number: 7417047
    Abstract: The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: August 26, 2008
    Assignee: Wyeth
    Inventors: Michael Sotirios Malamas, Ping Zhou, William Floyd Fobare, William Ronald Solvibile, Iwan Suwandi Gunawan, James Joseph Erdei, Yinfa Yan, Patrick Michael Andrae, Dominick Anthony Quagliato
  • Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines
    Patent number: 7378427
    Abstract: Synthetic methods are provided for production of compounds of the formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14 are as defined in the specification.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: May 27, 2008
    Assignee: Wyeth
    Inventors: Brian Hugh Ridgway, William Jay Moore, Mark Anthony Ashwell, William Ronald Solvibile, Amy Tsai-Ting Lee, Molly Elizabeth Hoke, Madelene Antane, Amedeo A. Failli
  • N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS
    Publication number: 20080119458
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor: wherein the variables are described in the specification.
    Type: Application
    Filed: October 5, 2007
    Publication date: May 22, 2008
    Applicant: Wyeth
    Inventors: William Ronald Solvibile, Ji-ln Kim, Marla Jean Williams, Jonathan Laird Gross, Albert Jean Robichaud
  • N-substituted-azacyclylamines as histamine-3 antagonists
    Publication number: 20070219240
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the histamine-3 receptor.
    Type: Application
    Filed: March 14, 2007
    Publication date: September 20, 2007
    Applicant: Wyeth
    Inventors: Derek Cecil Cole, Magda Asselin, Joseph Raymond Stock, Albert Jean Robichaud, Ji-In Kim, William Ronald Solvibile, Jonathan Laird Gross
  • Heterocyclic beta-3 adrenergic receptor agonists
    Patent number: 6605618
    Abstract: This invention provides compounds of Formula I having the structure wherein,  U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: August 12, 2003
    Assignee: Wyeth
    Inventors: Mark Anthony Ashwell, William Ronald Solvibile, Dominick Anthony Quagliato, Albert John Molinari
  • Heterocyclic &bgr;3 adrenergic receptor agonists
    Patent number: 6537994
    Abstract: This invention provides compounds of Formula I having the structure wherein, U, V, and W are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: March 25, 2003
    Assignee: Wyeth
    Inventors: Mark Anthony Ashwell, William Ronald Solvibile
  • Heterocyclic beta-3 adrenergic receptor agonists
    Publication number: 20030018045
    Abstract: This invention provides compounds of Formula I having the structure 1
    Type: Application
    Filed: July 2, 2002
    Publication date: January 23, 2003
    Applicant: Wyeth
    Inventors: Mark Anthony Ashwell, William Ronald Solvibile, Dominick Anthony Quagliato, Albert John Molinari
  • Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine &bgr;-3 adrenergic receptor agonists
    Patent number: 6506901
    Abstract: This invention provides compounds of Formula I having the structure wherein A, B, Z, R and R1 are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: January 14, 2003
    Assignee: Wyeth
    Inventors: Robert John Steffan, Mark Anthony Ashwell, Jeffrey Claude Pelletier, William Ronald Solvibile, Edward Martin Matelan
  • Heterocyclic &bgr;-3 adrenergic receptor agonists
    Patent number: 6451814
    Abstract: This invention provides compounds of Formula I having the structure U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: September 17, 2002
    Assignee: Wyeth
    Inventors: Mark Anthony Ashwell, William Ronald Solvibile, Dominick Anthony Quagliato, Albert John Molinari